Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374085 · ClinicalTrials.gov registry record · Phase 1
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT03374085 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 200 participants.
The verdict
NCT03374085, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.
Interventions
- DRUG Dexamethasone
- DRUG CC-92480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2025-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03374085
The ClinicalTrials.gov registry entry for NCT03374085 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT03374085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03374085 about?
NCT03374085 is a clinical study titled "A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)". This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible subjects must be previously treated with at least 3 ...
What is the current status of trial NCT03374085?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2018-02-06. Estimated completion is 2025-10-23.
What interventions are being tested in trial NCT03374085?
The interventions under investigation include: Dexamethasone (DRUG), CC-92480 (DRUG).
Who is sponsoring clinical trial NCT03374085?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.